Loading
Pooling over 5,000 patients, the IGCCCG classification sorted metastatic testicular cancer into good, intermediate and poor prognosis groups using tumour markers, primary site and non-lung metastases, and still decides how many cycles of chemotherapy a man receives.
Analysis of 5,202 patients with metastatic non-seminomatous and 660 with seminomatous germ cell tumours treated with cisplatin-based chemotherapy, identifying tumour marker levels (AFP, hCG, LDH), mediastinal primary site and non-pulmonary visceral metastases as independent prognostic factors and defining good (56 percent, 92 percent five-year survival), intermediate (28 percent, 80 percent) and poor (16 percent, 48 percent) prognosis groups for non-seminoma.
Three cycles of BEP for good risk and four for intermediate and poor risk follow directly from this classification, which was updated in 2021 with modern survival figures.
Shares Non-seminomatous germ cell tumour, Journal of Clinical Oncology.
Shares Seminoma, Journal of Clinical Oncology.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/